286 related articles for article (PubMed ID: 15304086)
41. Molecular analysis of a series of Israeli families with Comèl-Netherton syndrome.
Israeli S; Sarig O; Garty BZ; Indelman M; Bergman R; Sprecher E; Goldberg I
Dermatology; 2014; 228(2):183-8. PubMed ID: 24577329
[TBL] [Abstract][Full Text] [Related]
42.
Park NJ; Jo BG; Bong SK; Park SA; Lee S; Kim YK; Yang MH; Kim SN
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955819
[TBL] [Abstract][Full Text] [Related]
43. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
44. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
45. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome.
Hachem JP; Wagberg F; Schmuth M; Crumrine D; Lissens W; Jayakumar A; Houben E; Mauro TM; Leonardsson G; Brattsand M; Egelrud T; Roseeuw D; Clayman GL; Feingold KR; Williams ML; Elias PM
J Invest Dermatol; 2006 Jul; 126(7):1609-21. PubMed ID: 16601670
[TBL] [Abstract][Full Text] [Related]
46. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
47. Severe hypernatremic dehydration in an infant with Netherton syndrome.
Stoll C; Alembik Y; Tchomakov D; Messer J; Heid E; Boehm N; Calvas P; Hovnanian A
Genet Couns; 2001; 12(3):237-43. PubMed ID: 11693786
[TBL] [Abstract][Full Text] [Related]
48. LEKTI domain 15 is a functional Kazal-type proteinase inhibitor.
Vitzithum K; Lauber T; Kreutzmann P; Schulz A; Sommerhoff CP; Rösch P; Marx UC
Protein Expr Purif; 2008 Jan; 57(1):45-56. PubMed ID: 17936012
[TBL] [Abstract][Full Text] [Related]
49. Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in Spink5-/- mice.
Yang T; Liang D; Koch PJ; Hohl D; Kheradmand F; Overbeek PA
Genes Dev; 2004 Oct; 18(19):2354-8. PubMed ID: 15466487
[TBL] [Abstract][Full Text] [Related]
50. When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition.
Furio L; Hovnanian A
J Invest Dermatol; 2011 Nov; 131(11):2169-73. PubMed ID: 21997416
[TBL] [Abstract][Full Text] [Related]
51. An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation.
Macknet CA; Morkos A; Job L; Garberoglio MC; Clark RD; Macknet KD; Peverini RL
Pediatr Dermatol; 2008; 25(3):368-72. PubMed ID: 18577046
[TBL] [Abstract][Full Text] [Related]
52. [Netherton syndrome: a type of infantile erythroderma with failure to thrive, immune deficiency, rickets. Report of 3 cases].
André E; Till M; Descargues P; Cordier MP; Fouilhoux A; Haftek M; Hovnanian A; Lachaux A
Arch Pediatr; 2005 Sep; 12(9):1364-7. PubMed ID: 15935629
[TBL] [Abstract][Full Text] [Related]
53. The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome.
Bennett K; Heywood W; Di WL; Harper J; Clayman GL; Jayakumar A; Callard R; Mills K
J Proteomics; 2012 Jul; 75(13):3925-37. PubMed ID: 22588119
[TBL] [Abstract][Full Text] [Related]
54. Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion, stability, and subcellular distribution.
Jayakumar A; Kang Y; Henderson Y; Mitsudo K; Liu X; Briggs K; Wang M; Frederick MJ; El-Naggar AK; Bebök Z; Clayman GL
Arch Biochem Biophys; 2005 Mar; 435(1):89-102. PubMed ID: 15680911
[TBL] [Abstract][Full Text] [Related]
55. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.
Egelrud T; Brattsand M; Kreutzmann P; Walden M; Vitzithum K; Marx UC; Forssmann WG; Mägert HJ
Br J Dermatol; 2005 Dec; 153(6):1200-3. PubMed ID: 16307658
[TBL] [Abstract][Full Text] [Related]
56. A novel mutation in
Wang Y; Song H; Yu L; Wu N; Zheng X; Liang B; Wang P
Front Genet; 2022; 13():943264. PubMed ID: 36159989
[TBL] [Abstract][Full Text] [Related]
57. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
Schechter NM; Choi EJ; Wang ZM; Hanakawa Y; Stanley JR; Kang Y; Clayman GL; Jayakumar A
Biol Chem; 2005 Nov; 386(11):1173-84. PubMed ID: 16307483
[TBL] [Abstract][Full Text] [Related]
59. Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology.
Guo JZ; Su J; Dai H; Wang XY; Wu WB; Chen T; Zhang J; Wang WH
Eur J Dermatol; 2022 Jul; 32(4):459-463. PubMed ID: 36301754
[TBL] [Abstract][Full Text] [Related]
60. Genetic analysis of a severe case of Netherton syndrome and application for prenatal testing.
Müller FB; Hausser I; Berg D; Casper C; Maiwald R; Jung A; Jung H; Korge BP
Br J Dermatol; 2002 Mar; 146(3):495-9. PubMed ID: 11952552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
